


Evonik Capital Markets Day 2025

May 22, 2025



# Strong performance in 2024 and Q1 2025



Strong (out)performance as a credible base for our way ahead




<sup>1.</sup> Evonik adj. EBITDA growth vs. median earnings growth of peers (Arkema, BASF, Clariant, Covestro, Lanxess, Solvay, Syensqo, Wacker)

# **Evonik Capital Markets Day 2025 – Agenda**



Christian Kullmann
CEO
Strategy Update








Maike Schuh
CFO
Financial Perspective

Dr. Claudine Mollenkopf
COO

**Segment Advanced Technologies** 







Evonik Capital Markets Day 2025

Christian Kullmann, CEO Strategy Update



# **Table of contents**

- 1. Our new vision: Evonik is Industry's Superforce
- 2. Major milestone: Our 2027 targets



# The world is in constant turmoil for many years ...



Increasing environmental standards and regulation in Europe




War resulting in rising energy costs and corresponding inflation and loss of consumer confidence

2019

2020

2021

2024



Pandemic causes supply chain disruptions and changes in consumer patterns



End of multilateralism leading to global trade barriers

RISING PROTECTIONISM

ACCELERATING
CLIMATE CHANGE

INTENSIFYING COMPETITION



# ... and we have been proactively addressing resulting challenges since 2017

efficiency

mindset

#### **External challenges Strategic levers since 2017 Strategic progress Improved** >30% Sustainability **RISING Portfolio PROTECTIONISM** Americas sales share<sup>1</sup> **Balance** = better regional balance Innovation **Innovation ACCELERATING** Portfolio focused **CLIMATE** NEXTGEN 💥 faster sales CAGR **CHANGE** on NGS<sup>2</sup> NGS vs Non-NGS<sup>3</sup> Culture **Cost and** €250 m



short-term cost savings


in 2023 and 2024

**INTENSIFYING** 

COMPETITION

<sup>1.</sup> Excl. Performance Materials (C4) | 2. Products with superior sustainability profile according to our Portfolio Sustainability Assessment (PSA) | 3. 2023-2030E

# 2023 as starting point for multiple projects to set ourselves up for success






# Our new vision: Evonik is Industry's Superforce





# **Leading Portfolio:** New segment structure with tangible benefits



#### **Advanced Technologies**

Tailored solutions for our customers Innovation-driven Aim to expand market positions Product and solution excellence

Technology & cost leadership Process innovation Maintain leading market position Operational excellence



# 1 Leading Portfolio: Having both segments under one roof creates value

	Custom Solutions (CU)	Examples	Advanced Technologies (AT)
Secured independent financing of growth	Strong cash generation in AT finances innovation and growth		
Innovation synergies and know-how sharing	Innovation Growth Areas spread across both segments  Process optimization know-how of high relevance in AT and CU –  and product innovation in CU also of use for AT		
Complementary people skills	Different focus areas in each segment allow for better division of labor and creation of complementary competencies		
Scale benefits		d production & innovation with the design of	ation hubs s for AT also used in CU



# **Sustainable Innovation:** Main growth driver for the long-run

#### **Product innovation**



**Advance Precision Biosolutions** 

**Enable** Circular **Economy**  **Accelerate** Energy **Transition** 

#### **Process innovation**



**Advanced Process Control** 

**Innovative** waste heat up-cycling


**Process** redesign



<sup>1.</sup> Next Generation Solutions; products with superior sustainability profile according to our PSA analysis | 2. Green house gas emissions

# Regional Balance: Aiming for 1/3 of sa

# Aiming for 1/3 of sales in each region to be close to our customers




<sup>1.</sup> Excluding Performance Intermediates (C4)

**EVONIK**Leading Bevond Chemistry



# We are "Team Excellence": Derived from our core values – deeply rooted within Evonik





# **Table of contents**

1. Our new vision: Evonik is Industry's Superforce

2. Major milestone: Our 2027 targets



# In 2027 we reach a major milestone: €1bn additional adj. EBITDA

+€500 m from **GROWTH** 

+€500 m from **OPTIMIZATION** 

€1.7 bn

+€1 bn adj. EBITDA



# **Starting point** 2023

Base to be restated by planned divestments until 2027

## ... four years ...

Additional EBITDA is irrespective of planned divestments, i.e. targeted adj. EBITDA in 2027 will still be €1 bn higher vs (then lower) 2023 base

## Milestone 2027

Final value determined by planned divestments until 2027



# We harvest our growth investments and leverage market growth and innovation

### **Growth investments**

# Silica | United States

Metal Oxides | Japan

# **Market growth**

Additives for coatings Components for lithium batteries PU foam for insulation Active cosmetic ingredients Gas separation membranes

> relevant market 3-4% growth p.a.

#### **Innovation**



+€500 m

PA12 | Germany

Alkoxides | Singapore

adj. EBITDA from growth until 2027 (vs 2023)



# We set our organization and businesses up for long-term success

Group level

## Segment level

Group level

# **Reorganisation:** "Evonik Tailor Made"

Create a lean organisation that ideally supports our operating businesses

**Business optimization** 

Set up all operations businesses in a way so they "win" in their respective strategic role

**Procurement** optimization

Total spend optimization and digital sourcing



On track to deliver on ambitious savings target by the end of 2026

- Animal Nutrition (December 2023)
- Health Care (December 2024)



Silanes



New announcements



X-linkers



+€500 m

adj. EBITDA from optimization until 2027 (vs 2023)



# We continue to transform the portfolio

Long-term Today 2027

#### **New segments & differentiated business steering**

Divestment of **Performance Intermediates (C4)** 

(sales ~€1.9 bn)

Decision and execution on future of Marl and Wesseling (sales >€1 bn)

Portfolio finetuning in Health Care and **Coatings & Adhesive Resins** (total sales >€350 m)

Further portfolio finetuning

#### **Ongoing portfolio management**

- Focus within existing segment structure
- Strengthening innovation growth areas
- Aiming for a balanced regional split
- Continuous review of competitiveness of our assets



# **Our mid-term targets**

# **OUR TARGETS**

Fully aligned with our compensation system<sup>1</sup>

**UNTIL** 2027

+€1 bn

~11%

>40%

adj. EBITDA<sup>2</sup>

ROCE<sup>3</sup>

**Cash conversion rate**<sup>4</sup>

Solid investment grade rating

**UNTIL 2030** 

>50%

-25%

Sales share of NGS<sup>5</sup>

Reduction in GHG emissions<sup>6</sup>




<sup>1.</sup> KPIs part of annual short-term incentive system; ROCE to be decided on by 2026 AGM | 2. FY 2027 vs. FY 2023 | 3. Adj. EBIT / Capital Employed | 4. Free Cash Flow / Adj. EBITDA

<sup>5.</sup> Next Generation Solutions | 6. Green house gas emissions; scope 1 & 2 vs. base year 2021

# Our targets factor in both opportunities and risks

# **Opportunities**

- German stimulus package with expected >1pp additional German GDP growth p.a. (Germany 17% of Evonik sales)
- Declining energy costs either from relaxation of Russia/Ukraine war or from a global slowdown
- Contribution of "Optimization" programs largely independent of external environment



#### Risks

- Further escalating trade and tariff tensions
- Longer lasting lowgrowth environment globally or even global recession



# Long-term capital allocation policy

**INVESTMENTS** INTO **ORGANIC GROWTH** 

**ATTRACTIVE DIVIDEND** 

**UNTIL 2027: DE-LEVERAGING** NO M&A

**BEYOND 2027: TARGETED M&A**  **ADDITIONAL** SHARE-HOLDER RETURNS



# Why invest in Evonik?


Strong financial progress since 2024 and until 2027 – coming from own strength

Continued disciplined capital allocation with focus on organic growth and dividend

Portfolio transformation continues:

Divestments done until 2027 - creating additional capital allocation options

Clear improvement in shareholder structure: Less concentration, more balanced, RAG Stiftung no overhang any more







# **Evonik is Industry's Superforce:** We enable high-performing and sustainable solutions for our customers

#### **CONSUMER GOODS**

- ⊕ H<sub>2</sub>O<sub>2</sub> for food
- Environmentally-friendly solutions, e.g. water-based artificial leather











#### **BIOSURFACTANTS & BIOTECH ACTIVES**

- ⊕ Bio-based & fully biodegradable surfactants
- Biodegradable active cosmetic ingredients



#### **DESIGN FOR CIRCULARITY**

 Additives for extended durability of materials such as concrete and coatings



#### **FUTURE MOBILITY**

- Green tires
- Lightweight solutions
- Solutions for battery materials



#### **CELL CULTURE SOLUTIONS**

- Dipeptide
- Ingredients for Biopharmaceuticals



#### RECYCLING

- Catalysts enabling Recycling
- Enabling PU recycling



#### **ENVIRONMENT & UTILITIES**

- ⊕ Biogas/Hydrogen membranes
- Materials for windmills and PV
- Carbon capture and usage



#### **NUCLEIC ACID-BASED MEDICINES**

 Advanced oral & parenteral drug delivery systems (e.g. mRNA LNP)





# Innovation Growth Areas to generate additional sales of €1.5 bn by 2032

#### **Innovation Growth Areas**




**Advance Precision Biosolutions** 




**Enable Circular Economy** 




**Accelerate Energy Transition** 







# Evonik product portfolio is geared towards Next Generation Solutions (NGS) with a superior sustainability profile and above-average growth



45%

# +2pp Next Generation Solutions

Increased from 43 to ~45%; well on track for target of >50% by 2030

NGS sales share in 2024 (in %)



- Deliver superior sustainability benefits to our customers
- Adress increasing customer demand for sustainable solutions
- Substitute less sustainable solutions in the market
- Deliver above-average growth

Next Generation Solutions (NGS) = products with superior sustainability profile according to our Portfolio Sustainability Assessment (PSA) according to the World Council for Sustainable Development (WBCSD)



sustainability

profile

on market

average

sustainability

profile

above market

average

sustainability

profile

below market

average

# **Process innovation with Next Generation Technologies (NGT)**

#### **Process intensification**



Process optimization through e.g. advanced process control



Reduce emissions and losses for optimized output

#### Innovative waste heat up-cycling



Reduction of CO<sub>2</sub> emissions and costs through significant primary energy savings



Project EAGER potential: significant CO<sub>2</sub> savings with abatement cost lower than ETS certificate cost


#### **Process redesign**



Drive and apply circular and novel technologies



Key lever for long-term Scope 1,2 & 3 reduction targets





# **Development of shareholder structure:** Free float constantly increasing – no overhang due to RAG convertibles

